论文部分内容阅读
目的:研究化痰通络组方联合依达拉奉对脑梗死患者血清白介素-6(IL-6)、白介素-13(IL-13)及肿瘤坏死因子-α(TNF-α)表达水平的影响。方法:选取河北燕达医院2014年1月至2015年12月收治的脑梗死患者80例,按治疗方法将患者分为两组,各40例,两组患者均予以常规治疗,对照组在常规治疗上加用依达拉奉治疗,观察组在常规治疗上加用化痰通络组方联合依达拉奉治疗,观察两组患者治疗前与治疗1周、2周后血清IL-6、IL-13及TNF-α表达水平的变化及疗效。结果:治疗后观察组总有效率92.5%明显高于对照组(70.0%)(P<0.05);两组患者治疗前血清IL-6、IL-13及TNF-α水平比较,差异无统计学意义(P>0.05);治疗1周后比较,差异无统计学意义(P>0.05),但较同组治疗前比较,IL-6及TNF-α明显下降(P<0.05),IL-13水平上升(P<0.05);治疗2周后观察组IL-6、IL-13及TNF-α下降程度明显高于对照组(P<0.05);两组患者不良反应比较差异无统计学意义(P>0.05)。结论:化痰通络组方联合依达拉奉治疗脑梗死比依达拉奉单独治疗疗效更好,可有效降低血清IL-6、IL-13及TNF-α的表达水平,降低神经功能缺损程度,帮助患者恢复,且无明显不良反应。
Objective: To investigate the effect of Huatan Tongluo combined with edaravone on the expression of interleukin-6 (IL-6), interleukin-13 (IL-13) and tumor necrosis factor-α (TNF-α) in patients with cerebral infarction influences. Methods: Eighty patients with cerebral infarction who were treated in Hebei Yanda Hospital from January 2014 to December 2015 were divided into two groups according to the treatment method, 40 cases in each group. The patients in both groups were treated routinely, The treatment group was treated with edaravone. The observation group was treated with Huatan Tongluo combined with edaravone in the treatment group. The levels of IL-6, IL-13 and TNF-α expression levels and efficacy. Results: After treatment, the total effective rate in observation group was 92.5%, which was significantly higher than that in control group (70.0%) (P <0.05). There was no significant difference in serum IL-6, IL-13 and TNF- (P> 0.05). Compared with the same group before treatment, the levels of IL-6 and TNF-αdecreased significantly (P <0.05), IL-13 (P <0.05). After 2 weeks of treatment, the decrease of IL-6, IL-13 and TNF-α in the observation group was significantly higher than that in the control group (P <0.05). There was no significant difference in adverse reactions between the two groups P> 0.05). Conclusion: Huatan Tongluo combined with edaravone can treat cerebral infarction better than edaravone alone, which can effectively reduce the expression of IL-6, IL-13 and TNF-α, reduce the neurological deficit Extent, to help patients recover, and no obvious adverse reactions.